Printer Friendly

VITRO DIAGNOSTICS 1992 PRODUCT SALES INCREASE 296 PERCENT

 LITTLETON, Colo., March 1 /PRNewswire/ -- Vitro Diagnostics Inc. (OTC: Pink Sheets) reported substantially higher revenues for the fiscal year end of Oct. 31, 1992.
 Vitro's 1992 revenues from purified antigen sales were $191,851 or 296 percent more than the 1991 antigen sales. The total revenue for 1992 increased 186 percent to $259,794 from $139,889 in fiscal year 1991.
 With the new management team, established in 1989, Vitro has been transformed into a biotechnology company with a diverse product line. This transformation has reduced the net losses from $587,788 in 1990 to a net loss of $36,410 in 1992. The management believes that 1992 will be the last year for reporting losses.
 "Vitro has made a concerted effort to develop the purified antigen product line and we are beginning to see success. We anticipate that Vitro's revenues will continue to grow in the future as we pursue new markets and additions to our antigen line," said Dr. Jim Musick, Vitro's chief operating officer.
 Littleton-based Vitro Diagnostics produces and markets biological products used in diagnostic kits to test for causes of sterility and to diagnose and monitor the progression of cancer. It is one of the few manufacturers in the world that specializes in the purification of human pituitary hormones.
 -0- 3/1/93
 /CONTACT: Roger Hurst of Vitro Diagnostics, 303-794-2000/


CO: Vitro Diagnostics Inc. ST: Colorado IN: MTC SU:

BB -- DV001 -- 1250 03/01/93 09:11 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 1, 1993
Words:242
Previous Article:ROCKWELL AUTOMOTIVE PRESIDENT RONALD L. ROUDEBUSH TO BRIEF JOURNALISTS ON RECENT SUCCESSES AS HIS COMPANY DRIVES TO SALES GOAL
Next Article:UNION BANKSHARES PLANS INITIAL PUBLIC OFFERING
Topics:


Related Articles
THE ARES SERONO GROUP REPORTS SECOND QUARTER AND FIRST HALF 1992 RESULTS
LEECO DIAGNOSTICS ANNOUNCES RESTRUCTURING AND MERGER WITH ENDOGEN; SECOND QUARTER RESULTS
LEECO DIAGNOSTICS, INC. ANNOUNCES THIRD QUARTER RESULTS
ALAMAR BIOSCIENCES REPORTS FIRST QUARTER EARNINGS
LEECO ANNOUNCES 1992 RESULTS
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION SIGNS DEVELOPMENT AND LICENSE AGREEMENT FOR DNA PROBE TECHNOLOGY
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION REPORTS FIRST QUARTER 1993 FINANCIAL RESULTS
INTERNATIONAL MUREX TECHNOLOGIES CORPORATION REPORTS SECOND QUARTER 1993 FINANCIAL RESULTS
GAMMA BIOLOGICALS REPORTS STRONG EARNINGS FOR QUARTER AND SIX MONTHS ENDED SEPTEMBER 30, 1993
Vitro Diagnostics, Inc. 1996 Product Sales Increase 110%

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters